GlassScriptPhysician profile
Sarah Shami
NPI 1649660986
$1,953.47
in general payments reported to CMS, 2019-2025
27 companies · $486 in 2025
The $486 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $68.86 · 2022: $158 · 2023: $674 · 2024: $566 · 2025: $486.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,726.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,726.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $319.69 | 2023-2025 | Wegovy |
| Abbvie INC. | $257.09 | 2023-2024 | |
| Exeltis, USA INC. | $242.74 | 2022-2025 | Slynd |
| Evofem Biosciences, INC. | $155.37 | 2023-2025 | Phexxi, Solosec, Phexx |
| Astellas Pharma US INC | $108.79 | 2024-2025 | Veozah |
| Hologic Sales and Service, LLC | $97.77 | 2021-2025 | Aptima, Thinprep 2000 Processor |
| Sumitomo Pharma America, INC. | $83.08 | 2023-2025 | Myfembree, Gemtesa |
| Myovant Sciences INC. | $75.81 | 2021-2022 | |
| Exact Sciences Corporation | $74.43 | 2024-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $63.11 | 2023-2025 | |
| Millicent US INC | $60.79 | 2024-2025 | Intrarosa, Femlyv, Femring |
| Idorsia Pharmaceuticals US INC | $51.88 | 2023-2025 | Quviviq, Quviviq |
| Merck Sharp & Dohme LLC | $46.50 | 2023-2024 | Belsomra, Gardasil 9, Gardasil |
| Medtronic, INC. | $35.36 | 2025 | Signia |
| Organon LLC | $31.33 | 2023-2024 | Nexplanon |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $30.35 | 2022 | |
| Currax Pharmaceuticals LLC | $27.70 | 2023-2024 | Contrave |
| Pfizer INC. | $26.84 | 2023 | |
| Cepheid | $24.15 | 2025 | Genexpert |
| Gynesonics, INC. | $23.86 | 2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Mimedx Group, INC. | $23.82 | 2024 | |
| Coopersurgical, INC. | $19.13 | 2024 | Paragard T 380a |
| Mycovia Pharmaceuticals, INC. | $16.87 | 2023 | Vivjoa |
| Agile Therapeutics, INC. | $15.10 | 2024 | Twirla |
| Becton, Dickinson and Company | $14.61 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.96 | 2022 | |
| Mylan Pharmaceuticals INC. | $13.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Shami listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.